PROBLEM
Triple negative breast cancer is the most prevalent and the most aggressive form of breast cancer, comprising 15-20% of breast cancer cases. Current standard treatment utilizes traditional chemotherapies, but they have high toxicity and often result in cancers with drug resistance.
SOLUTION
Purdue researchers have developed a co-therapy to go along with current chemotherapies. It is able to generate synergistic activity against TNBC cells with Taxol, Cisplatin, Fluorouracil, or Methotrexate. Combinational therapy with the Purdue therapy not only shows a decrease in cell viability but the dosage of the chemotherapeutic is also reduced.
TECHNOLOGY VALIDATION
This technology has been validated using a transmission electron microscope, fluorescence microscopy and MTT assay. These methods demonstrated that the therapy works synergistically with known chemotherapeutics and identified the mode of cell death.
PRIMARY INVESTIGATOR
Meden F. Isaac-Lam, associate professor of chemistry, Purdue University Northwest
INNOVATION DISCLOSURE
Read More
LICENSING CONTACTS
Email: otcip@prf.org
MEDIA CONTACT
Email: Steve Martin // sgmartin@prf.org
